BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35050490)

  • 1. No Statistically Apparent Difference in Antifungal Effectiveness Observed Among Trimethoprim/Sulfamethoxazole Plus Clindamycin or Caspofungin, and Trimethoprim/Sulfamethoxazole Monotherapy in HIV-Infected Patients with Moderate to Severe Pneumocystis Pneumonia: Results of an Observational Multicenter Cohort Study.
    Huang Y; He X; Chen H; Harypursat V; Lu Y; Yuan J; Nie J; Liu M; Yu J; Zhang Y; Jiang Z; Qin Y; Xu L; Zhou G; Zhang D; Chen X; Zheng B; Chen Y
    Infect Dis Ther; 2022 Feb; 11(1):543-557. PubMed ID: 35050490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of initial caspofungin plus trimethoprim/sulfamethoxazole for severe PCP in patients without human immunodeficiency virus infection.
    Qi H; Dong D; Liu N; Xu Y; Qi M; Gu Q
    BMC Infect Dis; 2023 Jun; 23(1):409. PubMed ID: 37328748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-Dose vs Conventional-Dose Trimethoprim-Sulfamethoxazole Treatment for Pneumocystis Pneumonia in Patients Not Infected With HIV: A Multicenter, Retrospective Observational Cohort Study.
    Nagai T; Matsui H; Fujioka H; Homma Y; Otsuki A; Ito H; Ohmura S; Miyamoto T; Shichi D; Tomohisa W; Otsuka Y; Nakashima K
    Chest; 2024 Jan; 165(1):58-67. PubMed ID: 37574166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caspofungin combined with TMP/SMZ as a first-line therapy for moderate-to-severe PCP in patients with human immunodeficiency virus infection.
    Tian Q; Si J; Jiang F; Xu R; Wei B; Huang B; Li Q; Jiang Z; Zhao T
    HIV Med; 2021 Apr; 22(4):307-313. PubMed ID: 33277811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A regimen based on the combination of trimethoprim/sulfamethoxazole with caspofungin and corticosteroids as a first-line therapy for patients with severe non-HIV-related pneumocystis jirovecii pneumonia: a retrospective study in a tertiary hospital.
    Li H; Lu Y; Tian G; Wu Y; Chen T; Zhang J; Hu N; Wang X; Wang Y; Gao L; Yan J; Zhou L; Shi Q
    BMC Infect Dis; 2024 Jan; 24(1):152. PubMed ID: 38297200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study.
    Yamashita K; Shimomura Y; Ikesue H; Muroi N; Yoshimoto A; Hashida T
    BMC Infect Dis; 2021 Jul; 21(1):664. PubMed ID: 34238239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors and clinical efficacy of second-line treatments of Pneumocystis jirovecii pneumonia for non-HIV patients after first-line treatment failure.
    Liu A; Sun R; Cao G; Liu X; Zhu H; Yang J
    BMC Infect Dis; 2022 Jun; 22(1):546. PubMed ID: 35701759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clindamycin-primaquine for pneumocystis jiroveci pneumonia in renal transplant patients.
    Nickel P; Schürmann M; Albrecht H; Schindler R; Budde K; Westhoff T; Millward J; Suttorp N; Reinke P; Schürmann D
    Infection; 2014 Dec; 42(6):981-9. PubMed ID: 25168263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a prospective, randomized, controlled clinical trial. LFPMI Study Group. Ligue Française de Prévention des Maladies Infectieuses.
    May T; Beuscart C; Reynes J; Marchou B; Leclercq P; Borsa Lebas F; Saba J; Micoud M; Mouton Y; Canton P
    J Acquir Immune Defic Syndr (1988); 1994 May; 7(5):457-62. PubMed ID: 8158539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients.
    Podzamczer D; Santín M; Jimenez J; Casanova A; Bolao F; Gudiol GR
    AIDS; 1993 Apr; 7(4):501-6. PubMed ID: 8507417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for pneumocystis pneumonia: a pilot study in mice.
    Lobo ML; Esteves F; de Sousa B; Cardoso F; Cushion MT; Antunes F; Matos O
    PLoS One; 2013; 8(8):e70619. PubMed ID: 23940606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole.
    Fisher RG; Nageswaran S; Valentine ME; McKinney RE
    AIDS Patient Care STDS; 2001 May; 15(5):263-9. PubMed ID: 11530767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Four-Center Retrospective Study of the Efficacy and Toxicity of Low-Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Pneumonia in Patients without HIV Infection.
    Kosaka M; Ushiki A; Ikuyama Y; Hirai K; Matsuo A; Hachiya T; Hanaoka M
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim therapy for Pneumocystis jirovecii pneumonia in patients with systemic rheumatic diseases: A retrospective multicenter study.
    Ohmura SI; Naniwa T; Tamechika SY; Miyamoto T; Shichi D; Kazawa N; Iwagaitsu S; Maeda S; Wada JI; Niimi A
    J Infect Chemother; 2019 Apr; 25(4):253-261. PubMed ID: 30642768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation.
    Colby C; McAfee S; Sackstein R; Finkelstein D; Fishman J; Spitzer T
    Bone Marrow Transplant; 1999 Oct; 24(8):897-902. PubMed ID: 10516703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Pneumocystis carinii pneumonia in patients with AIDS.
    Wordell CJ; Hauptman SP
    Clin Pharm; 1988 Jul; 7(7):514-27. PubMed ID: 3138063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Pilot Study of Echinocandin Combination with Trimethoprim/Sulfamethoxazole and Clindamycin for the Treatment of AIDS Patients with Pneumocystis Pneumonia.
    Wang M; Lang G; Chen Y; Hu C; Guo Y; Tao R; Dong X; Zhu B
    J Immunol Res; 2019; 2019():8105075. PubMed ID: 31886310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
    Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
    J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS.
    Carr A; Tindall B; Penny R; Cooper DA
    AIDS; 1992 Feb; 6(2):165-71. PubMed ID: 1558714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label, randomized controlled trial of sulfamethoxazole-trimethoprim for
    Utsunomiya M; Dobashi H; Odani T; Saito K; Yokogawa N; Nagasaka K; Takenaka K; Soejima M; Sugihara T; Hagiyama H; Hirata S; Matsui K; Nonomura Y; Kondo M; Suzuki F; Nawata Y; Tomita M; Kihara M; Yokoyama-Kokuryo W; Hirano F; Yamazaki H; Sakai R; Nanki T; Koike R; Miyasaka N; Harigai M
    Rheumatol Adv Pract; 2020; 4(2):rkaa029. PubMed ID: 33134810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.